Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen (PSMA) from prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single photon emission computed tomography (SPECT).[1]
Early trials with yttrium (90Y) capromab pendetide were also conducted.[3]
References [edit]
- ^ a b Manyak, M. J. (2008). "Indium-111 capromab pendetide in the management of recurrent prostate cancer". Expert Review of Anticancer Therapy 8 (2): 175–122. doi:10.1586/14737140.8.2.175. PMID 18279057. edit
- ^ WHO Drug Information
- ^ Kahn, Daniel; J. Christopher Austin, Robert T. Maguire, Sara J. Miller, Jack Gerstbrein, Richard D. Williams (1999). "A Phase II Study of [90Y] Yttrium-Capromab Pendetide in the Treatment of Men with Prostate Cancer Recurrence Following Radical Prostatectomy". Cancer Biotherapy & Radiopharmaceuticals 14 (2): 99. doi:10.1089/cbr.1999.14.99.
|
|
|
| Tumor ("-t(u[m])-") |
|
Human ("-tumu-")
|
|
|
|
Mouse ("-tumo-")
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(capromab)
(what is this?) (verify)
